Abstract A087: BI KRASmulti, a First-in-class, Orally Bioavailable and Direct Inhibitor of Diverse Oncogenic KRAS Variants Drives Tumor Regression in KRAS G12V-driven Preclinical Models
Molecular Cancer Therapeutics(2023)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined